---
title: "Short Takes: June 13, 2025"
description: The latest news from the world of compounding
---

[APC Short Takes ](https://a4pc.org/apc-short-takes)

# [Short Takes: June 13, 2025](https://a4pc.org/apc-short-takes/short-takes-june-13-2025)

 Written by [Andrew](https://a4pc.org/apc-short-takes/author/andrew) | Jun 18, 2025, 3:49:57 PM

**This week in *****Compounding Interests***. Scott explains why it’s time for Congress to tell the FDA to stop trying to create a memorandum of understanding with states on interstate distributions of compounded medications. That MOU is based, he explains, on a now-obsolete, 1997 provision in the FD&C Act. Check out “[Let’s finally retire that MOU—and the 5% cap that comes with it](https://www.linkedin.com/pulse/lets-finally-retire-mouand-5-cap-comes-scott-brunner-cae-axkae/?_hsenc=p2ANqtz-_BC3ayBwWmLF0k_mf0oj5V3cEHC1rH_0iqsFreBYkWd7xZng6_Crgf6nx6_giWmt4UsRjV)”.

**Lilly locks out compounders**. Eli Lilly [now says](https://archive.ph/QTOKA?_hsenc=p2ANqtz-_BC3ayBwWmLF0k_mf0oj5V3cEHC1rH_0iqsFreBYkWd7xZng6_Crgf6nx6_giWmt4UsRjV) it will only work with telehealth firms that don’t offer compounded versions of semaglutide or tirzepatide. But some of those platforms *are* working with Novo Nordisk and continuing to offer compounded GLP-1s “to a limited group of patients who require non-standard [...] dosages of the medication.”

**…well, sort of.** Despite that agreement with Lilly, Yahoo! Finance in Australia is reporting that “[Eli Lilly telehealth partners continue to sell compounded GLP-1 weight-loss drugs despite agreement not to](https://au.finance.yahoo.com/news/eli-lilly-telehealth-partners-continue-to-sell-compounded-glp-1-weight-loss-drugs-despite-agreement-not-to-133253966.html?_hsenc=p2ANqtz-_BC3ayBwWmLF0k_mf0oj5V3cEHC1rH_0iqsFreBYkWd7xZng6_Crgf6nx6_giWmt4UsRjV)”.

**PBMs behind increasing BoP inspections and enforcement**. State boards of pharmacy are cracking down more on independent pharmacies — or at least inspecting them more often — [according to legal news site Mondaq](https://archive.ph/KzyuT?_hsenc=p2ANqtz-_BC3ayBwWmLF0k_mf0oj5V3cEHC1rH_0iqsFreBYkWd7xZng6_Crgf6nx6_giWmt4UsRjV). Why? A lot of it is pressure from PBMs, which can use a board’s disciplinary actions as a reason to kick a pharmacy from its network. (Or an entire pharmacy *network*; PBMs often have “cross-termination” contract clauses that mean one pharmacy’s discipline affects all its affiliated pharmacies. Unless, of course, it’s the PBMs’ own pharmacies.)

[View full post](https://a4pc.org/apc-short-takes/short-takes-june-13-2025)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Andrew"
  },
  "dateModified" : "2025-08-07T20:04:57.326Z",
  "datePublished" : "2025-06-18T15:49:57Z",
  "headline" : "Short Takes: June 13, 2025",
  "image" : {
    "@type" : "ImageObject",
    "height" : 722,
    "url" : "https://9189666.fs1.hubspotusercontent-na1.net/hubfs/9189666/Graphics/Short%20Takes-2.jpg",
    "width" : 1921
  },
  "mainEntityOfPage" : "https://a4pc.org/apc-short-takes/short-takes-june-13-2025",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "APC Short Takes"
  }
}
```